Table 2 NHL2 patient characteristics and... | American Society of Hematology

Table 2

NHL2 patient characteristics and outcomes by dose level

Patient number	CAR⁺ T-cell dose	Disease histology	Patient age (years)	KPS at HCT	Pre-HSCT disease status	Deauville score²⁴ before HSCT	Days to ANC ≥500	Best response	Disease status at data lock	Time (months) to progression or last follow-up
2-1	50 × 10⁶	MCL	57	100	CR1	1	10	Continuing CR	Continuing CR	14.1
2-2	50 × 10⁶	DLBCL	71	90	PR	3	10	CR	Progressed	12.6
2-3	50 × 10⁶	DLBCL	57	80	CR2	1	10	Continuing CR	Continuing CR	12.4
2-4	200 × 10⁶	MCL	63	100	CR1	1	11	Continuing CR	Continuing CR	12.3
2-5	200 × 10⁶	MCL	61	100	CR1	1	11	Continuing CR	Progressed	6.4
2-6	200 × 10⁶	DLBCL	67	100	PR	3	10	CR	CR	12.2
2-7	200 × 10⁶	MCL	62	90	CR1	1	12	Continuing CR	Continuing CR	12.3
2-8	200 × 10⁶	DLBCL	23	90	CR1	4	11	Continuing CR	Continuing CR	12.5

Patient number	CAR⁺ T-cell dose	Disease histology	Patient age (years)	KPS at HCT	Pre-HSCT disease status	Deauville score²⁴ before HSCT	Days to ANC ≥500	Best response	Disease status at data lock	Time (months) to progression or last follow-up
2-1	50 × 10⁶	MCL	57	100	CR1	1	10	Continuing CR	Continuing CR	14.1
2-2	50 × 10⁶	DLBCL	71	90	PR	3	10	CR	Progressed	12.6
2-3	50 × 10⁶	DLBCL	57	80	CR2	1	10	Continuing CR	Continuing CR	12.4
2-4	200 × 10⁶	MCL	63	100	CR1	1	11	Continuing CR	Continuing CR	12.3
2-5	200 × 10⁶	MCL	61	100	CR1	1	11	Continuing CR	Progressed	6.4
2-6	200 × 10⁶	DLBCL	67	100	PR	3	10	CR	CR	12.2
2-7	200 × 10⁶	MCL	62	90	CR1	1	12	Continuing CR	Continuing CR	12.3
2-8	200 × 10⁶	DLBCL	23	90	CR1	4	11	Continuing CR	Continuing CR	12.5